Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

December 1, 2015

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

Previous Article
St. Elizabeth Youngstown Hospital selects Sound Physicians to manage hospitalist services
St. Elizabeth Youngstown Hospital selects Sound Physicians to manage hospitalist services

Sound Physicians, a health care organization focused on improving quality and lowering cost throughout the ...

Next Article
AbilTo launches three-week Booster Program to address ongoing behavioral health challenges
AbilTo launches three-week Booster Program to address ongoing behavioral health challenges

AbilTo, Inc., the leading provider of tele-behavioral health programs proven to improve medical outcomes an...